Jayson Gesulga, PA
Physician Assistant · Urbandale, IANPI 1972989721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $629,796 of the $877,777 with a category attached, or 71.7%. 25 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 38.6% of the total. 2025 is the largest year on record at $299,643, 9.7 times the $30,829 reported in 2021. Among physician assistant clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,789 payments — averaging $490.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$339K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$212K
- Teva Pharmaceuticals USA, Inc.$107K
- Alkermes, Inc.$88K
- AbbVie$55K
- E.r. Squibb & Sons, L.L.C.$34K
- plus $42K from 19 others
What the payments were for
- Consulting fees$53,0046%
- Speaking & faculty fees$629,79672%
- Travel & lodging$164,88719%
- Food & beverage$29,5073%
- Education$5830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 522 | $338,849 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 383 | $212,161 |
| Teva Pharmaceuticals USA, Inc. | 208 | $107,278 |
| Alkermes, Inc. | 188 | $88,036 |
| AbbVie(2 entities) | 204 | $55,290 |
| E.r. Squibb & Sons, L.L.C. | 65 | $34,355 |
| Otsuka America Pharmaceutical, Inc. | 108 | $31,194 |
| Idorsia Pharmaceuticals US Inc | 16 | $6,149 |
| Neuronetics, Inc. | 3 | $1,687 |
| Axsome Therapeutics, Inc. | 18 | $607 |
| Johnson & Johnson | 22 | $528 |
| Lundbeck LLC | 12 | $317 |
| Sunovion Pharmaceuticals Inc. | 4 | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $294 |
| Vanda Pharmaceuticals Inc. | 5 | $170 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $151 |
| Boehringer Ingelheim | 2 | $85 |
| Novo Nordisk | 3 | $60 |
| Indivior Inc. | 3 | $60 |
| Bristol Myers Squibb | 1 | $56 |
| Almatica Pharma LLC | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$341,504
- INGREZZA$331,191
- CAPLYTA$207,415
- Austedo XR$75,177
- VRAYLAR$51,944
- COBENFY$32,236
- ABILIFY MAINTENA$29,309
- UZEDY$16,805
- AUSTEDO$12,104
- ABILIFY ASIMTUFII$11,213
- QUVIVIQ$5,907
- NEUROSTAR TMS THERAPY SYSTEM$1,590
- REXULTI$519
- ARISTADA$500
- SPRAVATO$150
- ARISTADA INITIO$125
- Auvelity$122
How this compares
$877,777 in reported general payments places this provider in the 95th percentile of 1,140 physician assistant providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 38 | $375,474 |
| AristadaAripiprazole Lauroxil | 28 | $87,077 |
| RexultiBrexpiprazole | 41 | $82,621 |
| Invega SustennaPaliperidone Palmitate | 25 | $67,363 |
| VraylarCariprazine Hcl | 46 | $65,988 |
| TrintellixVortioxetine Hydrobromide | 63 | $38,155 |
| Abilify MaintenaAripiprazole | 16 | $36,817 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $19,646 |
| QuviviqDaridorexant Hcl | 14 | $8,562 |
| EliquisApixaban | 23 | $6,827 |
| Aripiprazole | 62 | $4,897 |
| DayvigoLemborexant | 17 | $3,539 |
| Vilazodone Hcl | 39 | $3,188 |
| Clozapine | 31 | $3,070 |
| Divalproex Sodium ErDivalproex Sodium | 57 | $1,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $338,849 | $375,47438 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $31,194 | $119,43757 claims |
| Alkermes, Inc.Aristada, Lybalvi | $88,036 | $106,72342 claims |
| Johnson & JohnsonInvega Sustenna | $528 | $67,36325 claims |
| AbbVieVraylar | $55,290 | $65,98846 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $294 | $38,15563 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $6,149 | $8,56214 claims |
| Almatica Pharma LLCSertraline Hcl | $54 | $41155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in Urbandale
- Erin DohlmanUrbandale$4K
- Angela ConleyUrbandale$4K
- Laurie ClairJohnston$293K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
- Kelly MerchieDavenport$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.